204 related articles for article (PubMed ID: 27315223)
21. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.
Nilsson R; Jain M; Madhusudhan N; Sheppard NG; Strittmatter L; Kampf C; Huang J; Asplund A; Mootha VK
Nat Commun; 2014; 5():3128. PubMed ID: 24451681
[TBL] [Abstract][Full Text] [Related]
22. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.
Green NH; Galvan DL; Badal SS; Chang BH; LeBleu VS; Long J; Jonasch E; Danesh FR
Oncogene; 2019 Aug; 38(34):6211-6225. PubMed ID: 31289360
[TBL] [Abstract][Full Text] [Related]
23. Mild Choline Deficiency and MTHFD1 Synthetase Deficiency Interact to Increase Incidence of Developmental Delays and Defects in Mice.
Christensen KE; Malysheva OV; Carlin S; Matias F; MacFarlane AJ; Jacobs RL; Caudill MA; Rozen R
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35011003
[TBL] [Abstract][Full Text] [Related]
24. The importance of mitochondrial folate enzymes in human colorectal cancer.
Miyo M; Konno M; Colvin H; Nishida N; Koseki J; Kawamoto K; Tsunekuni K; Nishimura J; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M; Ishii H
Oncol Rep; 2017 Jan; 37(1):417-425. PubMed ID: 27878282
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.
Bonagas N; Gustafsson NMS; Henriksson M; Marttila P; Gustafsson R; Wiita E; Borhade S; Green AC; Vallin KSA; Sarno A; Svensson R; Göktürk C; Pham T; Jemth AS; Loseva O; Cookson V; Kiweler N; Sandberg L; Rasti A; Unterlass JE; Haraldsson M; Andersson Y; Scaletti ER; Bengtsson C; Paulin CBJ; Sanjiv K; Abdurakhmanov E; Pudelko L; Kunz B; Desroses M; Iliev P; Färnegårdh K; Krämer A; Garg N; Michel M; Häggblad S; Jarvius M; Kalderén C; Jensen AB; Almlöf I; Karsten S; Zhang SM; Häggblad M; Eriksson A; Liu J; Glinghammar B; Nekhotiaeva N; Klingegård F; Koolmeister T; Martens U; Llona-Minguez S; Moulson R; Nordström H; Parrow V; Dahllund L; Sjöberg B; Vargas IL; Vo DD; Wannberg J; Knapp S; Krokan HE; Arvidsson PI; Scobie M; Meiser J; Stenmark P; Berglund UW; Homan EJ; Helleday T
Nat Cancer; 2022 Feb; 3(2):156-172. PubMed ID: 35228749
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy.
Cheung CHY; Hsu CL; Tsuei CY; Kuo TT; Huang CT; Hsu WM; Chung YH; Wu HY; Hsu CC; Huang HC; Juan HF
Cell Death Dis; 2019 Oct; 10(11):786. PubMed ID: 31624245
[TBL] [Abstract][Full Text] [Related]
27. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
[TBL] [Abstract][Full Text] [Related]
28. Folate trapping is lethal to cancer cells.
Rather GM
Chem Biol Drug Des; 2023 Dec; 102(6):1588-1591. PubMed ID: 37620162
[TBL] [Abstract][Full Text] [Related]
29. Mammalian fibroblasts lacking mitochondrial NAD+-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase are glycine auxotrophs.
Patel H; Pietro ED; MacKenzie RE
J Biol Chem; 2003 May; 278(21):19436-41. PubMed ID: 12646567
[TBL] [Abstract][Full Text] [Related]
30. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
Li G; Wu J; Li L; Jiang P
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
[TBL] [Abstract][Full Text] [Related]
31. More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?
Zhu Z; Leung GKK
Front Oncol; 2020; 10():658. PubMed ID: 32411609
[TBL] [Abstract][Full Text] [Related]
32. Human mitochondrial MTHFD2 is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase.
Shin M; Momb J; Appling DR
Cancer Metab; 2017; 5():11. PubMed ID: 29225823
[TBL] [Abstract][Full Text] [Related]
33. The one-carbon metabolism pathway highlights therapeutic targets for gastrointestinal cancer (Review).
Konno M; Asai A; Kawamoto K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Int J Oncol; 2017 Apr; 50(4):1057-1063. PubMed ID: 28259896
[TBL] [Abstract][Full Text] [Related]
34. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.
Achreja A; Yu T; Mittal A; Choppara S; Animasahun O; Nenwani M; Wuchu F; Meurs N; Mohan A; Jeon JH; Sarangi I; Jayaraman A; Owen S; Kulkarni R; Cusato M; Weinberg F; Kweon HK; Subramanian C; Wicha MS; Merajver SD; Nagrath S; Cho KR; DiFeo A; Lu X; Nagrath D
Nat Metab; 2022 Sep; 4(9):1119-1137. PubMed ID: 36131208
[TBL] [Abstract][Full Text] [Related]
35. Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2).
Lee LC; Peng YH; Chang HH; Hsu T; Lu CT; Huang CH; Hsueh CC; Kung FC; Kuo CC; Jiaang WT; Wu SY
J Med Chem; 2021 Aug; 64(15):11288-11301. PubMed ID: 34337952
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development.
Tedeschi PM; Vazquez A; Kerrigan JE; Bertino JR
Mol Cancer Res; 2015 Oct; 13(10):1361-6. PubMed ID: 26101208
[TBL] [Abstract][Full Text] [Related]
37. MTHFD2 promotes ovarian cancer growth and metastasis via activation of the STAT3 signaling pathway.
Li Q; Yang F; Shi X; Bian S; Shen F; Wu Y; Zhu C; Fu F; Wang J; Zhou J; Chen Y
FEBS Open Bio; 2021 Oct; 11(10):2845-2857. PubMed ID: 34231329
[TBL] [Abstract][Full Text] [Related]
38. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
[TBL] [Abstract][Full Text] [Related]
39. Targeting MTHFD2 to Exploit Cancer-Specific Metabolism and the DNA Damage Response.
Ramos L; Henriksson M; Helleday T; Green AC
Cancer Res; 2024 Jan; 84(1):9-16. PubMed ID: 37922465
[TBL] [Abstract][Full Text] [Related]
40. Interference with MTHFD2 induces ferroptosis in ovarian cancer cells through ERK signaling to suppress tumor malignant progression.
Mo X; Liu Q; Liang K; Song Y
J Bioenerg Biomembr; 2024 Jun; 56(3):333-345. PubMed ID: 38488992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
